to_TO determine_VB treatment_NN and_CC predict_VBP outcome_NN ._.
In_IN prostate_NN cancer_NN ,_, for_IN example_NN ,_, a_DT linear_JJ model_NN of_IN a_DT single_JJ variable_NN ,_, a_DT laboratory_NN test_NN known_VBN as_IN PSA_NN ,_, has_VBZ been_VBN shown_VBN to_TO have_VB predictive_JJ value_NN for_IN survival_NN =_JJ -_: =[_NN 4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Recognizing_VBG the_DT limitations_NNS of_IN linear_JJ models_NNS for_IN realistic_JJ clinical_JJ variables_NNS ,_, Hellriegel_NNP et_FW al._FW developed_VBD a_DT segmented_JJ linear_JJ model_NN of_IN multiple_JJ sclerosis_NN progression_NN -LRB-_-LRB- 7_CD -RRB-_-RRB- ._.
This_DT paper_NN describes_VBZ our_PRP$ ef_NN
